Key elements of nutritional priorities to support GLP-1 therapy for obesity (A joint advisory from the American Society for Nutrition, the American College of Lifestyle medicine, the Obesity Medicine Association and the Obesity Society) Did you know WholisticMatters is powered by Standard Process
The reviews analysis confirms that synthetic GLP-1 medications like semaglutide and tirzepatide, originally developed to control blood sugar, offer clinically validated protection against cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD)-related outcomes, including improvements in steatosis and fibrosis-related endpoints
Insulin Resistance Insulin resistance affects approximately one in three adults and is frequently invisible for years
GLP-1 is produced by specific cells located in the intestines as a result of food intake
Given these anti-inflammatory effects, there is speculation that GLP-1 medicines could impair host immune defenses
Based on this Unger argued that disruptions to the release of glucagon played an important role in the development of type 2 diabetes
